Novo Nordisk Shares Fall After Late Stage Heart Drug Misses Key Trial Goal

The setback adds to growing investor concerns over the Danish drugmaker's product pipeline and execution strategy.

Novo Nordisk shares declined sharply on Friday after the pharmaceutical company announced that its experimental heart drug, ziltivekimab, failed to meet the primary objective of a late stage clinical trial, dealing another setback to the company's drug development pipeline.

The company's Copenhagen-listed shares fell as much as 10%, while its American depositary receipts (ADRs) were down about 8.6% in premarket trading following the announcement.

Novo Nordisk said the Phase 3 study found that ziltivekimab did not produce a statistically significant reduction in major adverse cardiovascular events (MACE) compared with a placebo. MACE is a commonly used clinical measure that includes cardiovascular death, non-fatal heart attack and non-fatal stroke.

Although the experimental treatment demonstrated biological activity by targeting the inflammatory IL-6 pathway, the observed effects did not translate into a meaningful reduction in cardiovascular events among patients enrolled in the study.

The trial involved more than 6,300 participants with atherosclerotic cardiovascular disease, chronic kidney disease and elevated levels of inflammation. Researchers evaluated whether adding ziltivekimab to standard treatment could lower the risk of a first major cardiovascular event.

Novo Nordisk said overall adverse event rates were comparable between the treatment and placebo groups. However, serious infections occurred more frequently among patients receiving ziltivekimab, while overall mortality remained similar across both groups.

Despite the disappointing outcome, the company said it remains committed to advancing treatments for cardiovascular disease.

Chief Scientific Officer Martin Holst Lange said the trial result would not alter Novo Nordisk's long-term strategy in the cardiovascular space, acknowledging that the company had hoped the drug would demonstrate a measurable clinical benefit.

The failed trial represents another challenge for Novo Nordisk as it works to strengthen investor confidence in its research pipeline and commercial execution, particularly in the competitive U.S. market. Prior to Friday's decline, the company's Copenhagen-listed shares had already fallen approximately 7% since the start of the year.

The clinical trial findings are based solely on information released by Novo Nordisk. Independent verification of the results was not available from the material provided.

Comments (0)

You must be logged in to post comments.

No comments yet. Be the first to start the conversation!

Load More Comments